Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 6Other hematologic neoplasm 5Lymphoid 5Myeloid 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 15Whole-Body Irradiation 9Peripheral Blood Stem Cell Transplantation 8Mycophenolic Acid 8Cyclosporine 8Cyclophosphamide 7Tacrolimus 5Filgrastim 5Cytarabine 5Carboplatin 4Azacitidine 4olaparib 3Thiotepa 3Lenalidomide 3Etoposide 3Bortezomib 3Biopsy 3Antilymphocyte Serum 3venetoclax 2tipifarnib 2sargramostim 2peginesatide 2laromustine 2hematide 2enasidenib 2alvocidib 2aldesleukin 2Vorinostat 2Tretinoin 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × 7-hydroxystaurosporine × Classical hematology × Clear all
NCT00004263 2012-07-30

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1 Completed
16 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡